SCHEMBL2452085

SCHEMBL2452085

Cc1n[nH]c(=O)c(-c2cccs2)c1-c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMP P19971 1/20 0.46
CHEK1 O14757 2/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
NOTUM Q6P988 1/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39
STAT6 P42226 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4608946 0.82 TYMP (0.46) TYMPCHEK1GRIN2DGRIN3BGRIN1
SCHEMBL4583927 0.80 TYMP (0.47) TYMPCHEK1GRIN2DGRIN3BGRIN1
SCHEMBL2454153 0.78 NOTUM (0.41) CHEK1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4584726 0.78 TYMP (0.45) TYMPGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL896729 0.77 DRD1 (0.42) CHEK1NOTUMMAPTLMNAIKBKB
SCHEMBL2457386 0.76 PTGS1 (0.42) NOTUMALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL2351250 0.76 NPC1 (0.40) CHEK1NOTUMMAPTSMN1; SMN2MEN1
SCHEMBL4652959 0.75 RAB9A (0.47) NOTUMMAPTALDH1A1POLBMEN1
SCHEMBL895857 0.75 TRPV1 (0.44) IKBKBMAP3K14
SCHEMBL896628 0.75 DRD1 (0.43) NOTUMIKBKBMAP3K14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1958948-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-10-05 EP disclosed
EP-1958948-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-10-05 EP disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
EP-1974608-A1 Arylpyridazines as fungicides Bayer CropScience AG (DE) 2008-10-01 EP disclosed
EP-1974608-A1 Arylpyridazines as fungicides Bayer CropScience AG (DE) 2008-10-01 EP disclosed
EP-1958948-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed
EP-1958948-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156608-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, PDXK TYMP 724/4885CHEK1 4256/4885GRIN2D 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.